Study Phase 2

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

Trial Information

Generic NameInfliximabProduct NameREMICADE®Therapeutic AreaAntineoplastic and Immunomodulating AgentsProduct ClassImmunosuppressantsCondition StudiedArthritis, RheumatoidChemical SubgroupsN/APharmacological SubgroupsN/A
Sponsor Protocol NumberC0168T14Enrollment101Data PartnerJohnson & Johnson% Female73.4%Mean/Median Age (Years)52% White96%

Supporting Documentation

  • Collected Datasets Available
  • Data Definition Specification Available
  • Clinical Study Report Available

Approved Data Requests Associated with this Trial

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.